Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration

Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration

Graft-versus-host disease (GVHD) remains the major cause of mortality and morbidity in non-relapse patients after allogeneic hematopoietic cell transplantation (allo-HCT). As the number of patients undergoing allo-HCT increases, it will become imperative to determine safe and effective treatment opt...

Full description

Bibliographic Details
Main Authors: Yang Gao, Wei Shan, Tianning Gu, Jie Zhang, Yibo Wu, Xiaoqing Li, Xiangjun Zeng, Hongyu Zhou, Zhi Chen, Haowen Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Immunology
Subjects:
daratumumab
CD38
graft-versus-host disease
graft-versus-leukemia
chemokine
chemoattractant receptor
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.785774/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.785774/full

Similar Items